Literature DB >> 1902259

Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan.

H A Pretus1, H E Ensley, R B McNamee, E L Jones, I W Browder, D L Williams.   

Abstract

Herein we describe the isolation, physicochemical characterization and preclinical evaluation of a water-soluble biologic response modifier extracted from Sclerotium glucanicum. Alkaline extraction of insoluble S. glucanicum exopolymers produced a soluble scleroglucan composed of a triple-helical beta-1,3-linked glucopyranose backbone with single beta-1,6-linked glucopyranosyl branches every third subunit. Scleroglucan has a weight average molecular mass of 1.56 x 10(6) Da, a weight average root mean square distance from the center of gravity of the molecule to its farthest elements of 51.8 nm, a polydispersity (weight-average molecular mass/number average molecular mass) of 1.83 and intrinsic viscosity of 3.081 dl/g. Scleroglucan (250 mg/kg, intravenously) stimulated in vivo murine macrophage phagocytic activity (66%, P less than .001) and increased in vitro macrophage tumor cytotoxicity against syngeneic tumor targets by 124% (P less than .05). Scleroglucan enhanced (P less than .001) murine bone marrow proliferation in a biphasic manner by up to 328%. Scleroglucan therapy increased survival of mice challenged with syngeneic lymphoma, melanoma or adenocarcinoma. AKR/J mice bearing syngeneic lymphoma (1 x 10(3) cells, intraperitoneally) demonstrated increased (P less than .001) long-term survival (100% vs. 0%, greater than 64 days). C57Bl/6J mice bearing syngeneic melanoma B16 (5 x 10(5) cells, subcutaneously) demonstrated increased long-term survival (64% vs. 0%, P less than .05). C57Bl/6J mice bearing syngeneic adenocarcinoma BW10232 (1 x 10(5) cells, subcutaneously) demonstrated increased (P less than .05) median survival time. In addition, scleroglucan prophylaxis increased resistance of mice to challenge with Staphylococcus aureus, Candida albicans and mouse hepatitis virus A-59. Scleroglucan did not induce toxicity or hepatomegaly. We conclude that: 1) a branched, water-soluble beta-1,3-linked scleroglucan biologic response modifier can be extracted from S. glucanicum; 2) scleroglucan will stimulate immunity, modify experimental neoplastic disease and increase resistance to microbial challenge; and 3) scleroglucan shows promise as an immunopotentiating drug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902259

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.

Authors:  Courtni T Newsome; Estefany Flores; Alfred Ayala; Stephen Gregory; Jonathan S Reichner
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

3.  Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes.

Authors:  Katarina Bergendiova; Elena Tibenska; Juraj Majtan
Journal:  Eur J Appl Physiol       Date:  2011-01-20       Impact factor: 3.078

4.  Dendritic cell interaction with Candida albicans critically depends on N-linked mannan.

Authors:  Alessandra Cambi; Mihai G Netea; Hector M Mora-Montes; Neil A R Gow; Stanleyson V Hato; Douglas W Lowman; Bart-Jan Kullberg; Ruurd Torensma; David L Williams; Carl G Figdor
Journal:  J Biol Chem       Date:  2008-05-15       Impact factor: 5.157

5.  Carboxymethyl derivative of scleroglucan: a novel thermosensitive hydrogel forming polysaccharide for drug delivery applications.

Authors:  Michelle Feeney; Maria Antonietta Casadei; Pietro Matricardi
Journal:  J Mater Sci Mater Med       Date:  2009-01-10       Impact factor: 3.896

6.  Effects after inhalation of (1-->3)-beta-D-glucan in healthy humans.

Authors:  J Thorn; L Beijer; R Rylander
Journal:  Mediators Inflamm       Date:  2001-08       Impact factor: 4.711

Review 7.  Immunomodulation of Fungal β-Glucan in Host Defense Signaling by Dectin-1.

Authors:  Sainkhuu Batbayar; Dong Hee Lee; Ha Won Kim
Journal:  Biomol Ther (Seoul)       Date:  2012-09       Impact factor: 4.634

Review 8.  Beta-glucan contamination of pharmaceutical products: How much should we accept?

Authors:  Claire Barton; Kim Vigor; Robert Scott; Paul Jones; Heike Lentfer; Heather J Bax; Debra H Josephs; Sophia N Karagiannis; James F Spicer
Journal:  Cancer Immunol Immunother       Date:  2016-07-29       Impact factor: 6.968

9.  Immunomodulatory Activity of the Water Extract from Medicinal Mushroom Inonotus obliquus.

Authors:  Yeon-Ran Kim
Journal:  Mycobiology       Date:  2005-09-30       Impact factor: 1.858

Review 10.  Microbial production of scleroglucan and downstream processing.

Authors:  Natalia A Castillo; Alejandra L Valdez; Julia I Fariña
Journal:  Front Microbiol       Date:  2015-10-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.